PROSPECTS AND CONSEQUENCES OF HORMONE REPLACEMENT THERAPY IN CANCERS A REVIEW
Abstract
Hormone replacement therapy (estrogens with or without progestogens) is widely used medication therapy worldwide for alleviating post menopausal symptoms. The association of Hormone replacement therapy (HRT) and risk of cancers leads to many studies. A lot of controversial results regarding the risk of cancers arises which leads to many questions that are still unanswered and can be cleared by further extensive research. There is considerable uncertainty among general practitioners to balance the beneficial and harmful effects of long term HRT particularly regarding the risk of cancers (breast, ovarian, endometrial, colorectal, lung cancers, lymphoma’s and leukaemia’s). The goal of HRT is not only to normalize the follicle stimulating hormone value, but rather to use the minimum effective dosage to suppress vasomotor reactions, treat urogenital atrophy, prevent trabecular and cortical bone loss, and reduce cardiac risk. Use of HRT should be individualized for risks and benefits of each patient that is being taken into consideration.
Keywords:
Hormone replacement therapy, menopausal symptoms, cancers, risks and benefitsDOI
https://doi.org/10.25004/IJPSDR.2014.060201References
2. Brett KM, Madans JH. Use of Postmenopausal Hormone Replacement Therapy: Estimates from a Nationally Representative Cohort Study. Am J Epidemiol 1997; 145:536-45.
3. Grady D, Ernster VL. Hormone Replacement Therapy and Endometrial Cancer: Are Current Regimens Safe? Journal of the National Cancer Institute 1997; 89(15):1088-1089.
4. Thacker HL. Current issues in menopausal hormone replacement therapy. Cleveland Clinic Journal of Medicine 1996; 63(6):344-353.
5. Wilkes HC, Meade TW. Hormone replacement therapy in general practice: a survey of doctors in the MRC's general practice research framework. BMJ 1991; 302:1317-20.
6. Minelli C, Abrams KR, Sutton AJ, Cooper NJ. Benefits and harms associated with hormone replacement therapy: clinical decision analysis. BMJ 2004; 328:1-6
7. Krieger et al. Hormone replacement therapy, cancer, controversies, and women’s health: historical, epidemiological, biological, clinical, and advocacy perspectives. J Epidemiol Community Health 2005; 59:740-748.
8. Humphries KH, Gill S. Risks and benefits of hormone replacement therapy: The evidence speaks. CMAJ 2003; 168(8):1001-10.
9. Jacobs HS. Hormone replacement therapy and breast Cancer. Endocrine-Related Cancer 2000; 7; 53-61.
10. McCullough et al. Body Mass and Endometrial Cancer Risk by Hormone Replacement Therapy and Cancer Subtype. Cancer Epidemiol Biomarkers Prev 2008; 17(1):73-79.
11. Colditz GA. Relationship between Estrogen Levels, Use of Hormone Replacement Therapy, and Breast Cancer. J Natl Cancer Inst 1998; 90:814–23.
12. Santen RJ et al. Risk of Breast Cancer with Progestins in Combination with Estrogen as Hormone Replacement Therapy. JCE & M 2001; 86(1):16-23.
13. Greiser CM, Greiser EM, Dören M. Menopausal hormone therapy and risk of breast cancer:a meta-analysis of epidemiological studies and randomizedcontrolled trials. Human Reproduction Update 2005; 11(6):561-573.
14. Mayer ME. Hormone replacement and breast cancer: implications of the iowa women's health study. Cleveland Clinic Journal of Medicine 1999; 66(10): 608-613.
15. Stallard S, Litherland JC, Cordiner CM, Dobson HM, George WD, Mallon EA, Hole D. Effect of hormone replacement therapy on the pathological stage of breast cancer: population based, cross sectional study. BMJ 2000; 320:348-9.
16. Stahlberg et al. Breast cancer incidence, case-fatality and breast cancer mortality in Danish women using hormone replacement therapy- a prospective observational study. International Journal of Epidemiology 2005; 34:931-935.
17. Chiarelli et al. Influence of Patterns of Hormone Replacement Therapy Use and Mammographic Density on Breast Cancer Detection, Cancer Epidemiol Biomarkers Prev 2006; 15(10):1856-62.
18. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of Hormone Replacement Therapy on Breast Cancer Risk: Estrogen Versus Estrogen Plus Progestin. J Natl Cancer Inst 2000; 92:328–32.
19. Barrett-connor E, Stuenkel CA. Hormone replacement therapy-risks and benefits, Int.J.epidemiology 2001; 30:423-426.
20. Batur P, Thacker HL, Moore HCF. Discussing breast cancer and hormone replacement therapy with women. Cleveland Clinic Journal of Medicine 2002; 69(11):838-848.
21. Brinton et al. Menopausal Hormone Therapy and Breast Cancer Risk in the NIH-AARP Diet and Health Study Cohort. Cancer Epidemiol Biomarkers Prev 2008; 17(11):3150–60.
22. Ursin et al. Does Menopausal Hormone Replacement Therapy Interact With Known Factors to Increase Risk of Breast Cancer? J Clin Oncol 2002; 20:699-706.
23. Daling et al. Association of Regimens of Hormone Replacement Therapy to Prognostic Factors among Women Diagnosed with Breast Cancer Aged 50-64 Years. Cancer Epidemiol Biomarkers Prev 2003; 12:1175-1181.
24. Marsden J, A’Hern R. Progestogens and breast cancer risk: the role of hormonal contraceptives and hormone replacement therapy. Journal of Family Planning and Reproductive Health Care 2003; 29(4): 185-187.
25. Rebbeck et al. Effect of Short-Term Hormone Replacement Therapy on Breast Cancer Risk Reduction after Bilateral Prophylactic Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study Group. J Clin Oncol 2005, 23:7804-7810.
26. Simpson JA, English DR, MacInnis RJ, Gertig DM, Hopper JL, Giles GG. A comparison of different methods for including ‘age at menopause’ in analyses of the association between hormone replacement therapy use and breast cancer. J Fam Plann Reprod Health Care 2007; 33(1): 11-16.
27. Shantakumar et al. Age and Menopausal Effects of Hormonal Birth Control and Hormone Replacement Therapy in Relation to Breast Cancer Risk. Am J Epidemiol 2007; 165:1187-1198.
28. Holmberg et al. Increased Risk of Recurrence after Hormone Replacement Therapy in Breast Cancer Survivors. J Natl Cancer Inst 2008; 100: 475-482.
29. Corrao et al. Menopause hormone replacement therapy and cancer risk: an Italian record linkage investigation. Annals of Oncology 2008; 19: 150-155.
30. Slanger et al. Menopausal Hormone Therapy and Risk of Clinical Breast Cancer Subtypes. Cancer Epidemiol Biomarkers Prev 2009; 18(4):1188–96.
31. Renard F, Vankrunkelsven P, Van Eycken L, Henau K, Boniol M, Autier P. Decline in breast cancer incidence in the Flemish region of Belgium after a decline in hormonal replacement therapy. Annals of Oncology 2010; 21: 2356-2360.
32. De P, Ineke Neutel C, Olivotto I, Morrison H. Breast Cancer Incidence and Hormone Replacement Therapy in Canada. J Natl Cancer Inst 2010; 102:1489-1495.
33. Zbuk K, Anand SS. Declining incidence of breast cancer after decreased use of hormone-replacement therapy: magnitude and time lags in different countries. J Epidemiol Community Health 2012; 66:1-7.
34. Shapiro S, Farmer RDT, Seaman H, Stevenson JC, Mueck AO. Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies, Part 1. The Collaborative Reanalysis. J Fam Plann Reprod Health Care 2011; 37:103-109.
35. Shapiro S, Farmer RDT, Seaman H, Stevenson JC, Mueck AO. Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies, Part 2. The Women’s Health Initiative: estrogen plus progestogen. J Fam Plann Reprod Health Care 2011; 37:103-109.
36. Shapiro S, Farmer RDT, Seaman H, Stevenson JC, Mueck AO. Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies, Part 3. The Women’s Health Initiative: unopposed estrogen. J Fam Plann Reprod Health Care 2011; 37:103-109.
37. Shapiro S, Farmer RDT, Stevenson JC, Burger HG, Mueck AO. Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies, does hormone replacement therapy cause breast cancer? An application of causal principles to three studies, Part 4. The Million Women Study. J Fam Plann Reprod Health Care 2012; 38:102-109.
38. Pike et al. Estrogen–Progestin Replacement Therapy and Endometrial Cancer. J Natl Cancer Inst 1997; 89:1110-6.
39. Strom et al. Case-Control Study of Postmenopausal Hormone Replacement Therapy and Endometrial Cancer. Am J Epidemiol 2006; 164:775-786.
40. Rebbeck et al. Estrogen Sulfation Genes, Hormone Replacement Therapy, and Endometrial Cancer Risk J Natl Cancer Inst 2006; 98: 1311 – 20.
41. Razavi P, Pike MC, Horn-Ross PL, Templeman C, Bernstein L, Ursin G. Long-term Postmenopausal Hormone Therapy and Endometrial Cancer. Cancer Epidemiol Biomarkers Prev 2010; 19(2); 475-83.
42. McCullough et al. Body Mass and Endometrial Cancer Risk by Hormone Replacement Therapy and Cancer Subtype. Cancer Epidemiol Biomarkers Prev 2008; 17(1):73-79.
43. Crosbie EJ, Zwahlen M, Kitchener HC, Egger M, Renehan AG. Body Mass Index, Hormone Replacement Therapy, and Endometrial Cancer Risk: A Meta-Analysis. Cancer Epidemiol Biomarkers Prev 2010; 19(12): 3119-30.
44. Greiser CM, Greiser EM, Do¨ren M. Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis. Human Reproduction Update 2007; 13(5):453-463.
45. Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, Weiderpass E. Hormone Replacement Therapy and the Risk of Invasive Epithelial Ovarian Cancer in Swedish Women. J Natl Cancer Inst 2002; 94:497-504.
46. Rossing MA, Cushing-Haugen KL, Wicklund KG, Doherty JA, Weiss NS. Menopausal Hormone Therapy and Risk of Epithelial Ovarian Cancer. Cancer Epidemiol Biomarkers Prev 2007; 16:2548-2556.
47. Morch LS, Løkkegaard E, Andreasen AH, Kjær KS, Lidegaard Ø. Hormone Therapy and Different Ovarian Cancers: A National Cohort Study. Am J Epidemiol. 2012; 175(12):1234-1242.
48. Dietel M, Lewis MA, Shapiro S. Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Human Reproduction 2005; 20(8):2052-2060.
49. Fernandez E, Franceschi S, Vecchia CL. Colorectal cancer and hormone replacement therapy: a review of epidemiological studies. Menopause Int 2000; 6: 8-14.
50. Fernandez E, Vecchia CL, Braga C, Talamini R, Negri E, Parazzini F, Franceschi S. Hormone replacement therapy and risk of colon and rectal cancer. Cancer epidemiology, biomarkers and prevention 1998; 7:329-333.
51. Johnson et al. Menopausal Hormone Therapy and Risk of Colorectal Cancer. Cancer Epidemiol Biomarkers Prev 2009; 18(1):196-203.
52. Rennert G, Rennert HS, Pinchev M, Lavie O, Gruber SB. Use of Hormone Replacement Therapy and the Risk of Colorectal Cancer. J Clin Oncol 2009; 27:4542-4547.
53. Henderson et al. Menopausal Hormone Therapy Use and Risk of Invasive Colon Cancer The California Teachers Study. Am J Epidemiol 2010; 171:415-425.
54. Schabath MB, Wu X, Vassilopoulou-Sellin R, Vaporciyan AA, Spitz MR. Hormone Replacement Therapy and Lung Cancer Risk: A Case- Control Analysis. Clin Cancer Res 2004; 10:113-123.
55. Chien JW, Au DH, Satia JA, White E. Lung Cancer and Hormone Replacement Therapy: Association in the Vitamins and Lifestyle Study. J Clin Oncol 2010; 28:1540-1546.
56. Cerhan et al. Hormone Replacement Therapy and Risk of Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Cancer Epidemiol Biomarkers Prev 2002; 11:1466-1471.
Published

